- Conditions
- COVID-19 Testing Behaviors
- Interventions
- COVID-19 rapid test-to-treat, Standard COVID19 education control arm
- Behavioral
- Lead sponsor
- University of Missouri, Kansas City
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 900 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Kansas City, Missouri
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 552
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Local Anesthesia
- Interventions
- lidocaine, sodium bicarbonate
- Drug
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years to 100 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Advanced Unresectable or Metastatic Solid Malignancy
- Interventions
- Entrectinib, Inavolisib, Alectinib, Ipatasertib, Atezolizumab, Trastuzumab Emtansine, Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf, Tucatinib, Investigator's Choice of Chemotherapy, Paclitaxel, Tiragolumab, Pralsetinib
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 252 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 38
- States / cities
- Anchorage, Alaska • Oro Valley, Arizona • Hot Springs, Arkansas + 33 more
- Conditions
- Advanced or Metastatic Solid Tumors
- Interventions
- ERAS-007, ERAS-601
- Drug
- Lead sponsor
- Erasca, Inc.
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 5
- States / cities
- Denver, Colorado • Sarasota, Florida • Nashville, Tennessee + 2 more
- Conditions
- Anxiety, PTSD, ADHD, Depression Disorders, Post-traumatic Stress, Substance Use, Executive Function, Sleep Disturbance
- Interventions
- AIP-Informed Integrative Psychotherapy, Transcutaneous Auricular Vagus Nerve Stimulation, Regulated Breathing and Autonomic Regulation, Audiovisual Entrainment, Vibroacoustic Stimulation, Breathwork-Based Auditory Driving Entropy Module (BADEM), Transcranial Electrical Stimulation
- Behavioral · Device
- Lead sponsor
- Tactical Mind Research Coalition, Inc.
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Glioma
- Interventions
- Biospecimen Collection, Dasatinib, Fisetin, Magnetic Resonance Imaging, Patient Observation, Positron Emission Tomography, Quercetin, Temozolomide, Topoisomerase-1 Inhibitor LMP744, Single Agent Therapy
- Procedure · Drug · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Diffuse Midline Glioma (DMG), Glioblastoma, Recurrent Ependymoma, Recurrent Malignant Central Nervous System Neoplasm, Spinal Cord Glioma, World Health Organization (WHO) Grade III Glioma, CNS Tumor, Central Nervous System Tumor
- Interventions
- ONC206, Standard of Care Radiation Therapy, Optional Proton (1H) MR spectroscopy (MRS)
- Drug · Radiation · Procedure
- Lead sponsor
- Sabine Mueller, MD, PhD
- Other
- Eligibility
- 2 Years to 21 Years
- Enrollment
- 208 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 5
- States / cities
- San Francisco, California • Washington D.C., District of Columbia • Atlanta, Georgia + 2 more
- Conditions
- Multiple Myeloma
- Interventions
- Etentamig (ABBV-383)
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 27
- States / cities
- Phoenix, Arizona • Springdale, Arkansas • Aurora, Colorado + 23 more
- Conditions
- Influenza
- Interventions
- GSK influenza virus H5N1 vaccine 1557484A
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2013
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia • Bethesda, Maryland • Silver Spring, Maryland
- Conditions
- Fatigue in Multiple Sclerosis
- Interventions
- Amantadine, Modafinil, Methylphenidate, Placebos
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 141 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 2
- States / cities
- San Francisco, California • Baltimore, Maryland
- Conditions
- Multiple Myeloma
- Interventions
- Ixazomib, Melphalan, Prednisone
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 2
- States / cities
- Lebanon, New Hampshire • Morgantown, West Virginia
- Conditions
- Multiple Myeloma
- Interventions
- BMS-986393, Alnuctamab, Mezigdomide, Iberdomide, Elranatamab, Dexamethasone
- Drug
- Lead sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 187 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 11 more
- Conditions
- Psoriasis
- Interventions
- ABBV-553, Placebo
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 4
- States / cities
- Anaheim, California • Toluca, California • Port Orange, Florida + 1 more
- Conditions
- High Grade Osteosarcoma, Localized Osteosarcoma, Metastatic Osteosarcoma, Secondary Osteosarcoma
- Interventions
- Bone Scan, Cabozantinib S-malate, Cisplatin, Computed Tomography, Doxorubicin Hydrochloride, Magnetic Resonance Imaging, Methotrexate, Surgical Procedure, X-Ray Imaging
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 40 Years
- Enrollment
- 1,122 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 181
- States / cities
- Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 134 more
- Conditions
- Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL), Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)
- Interventions
- Ibrutinib, HD- Methotrexate (MTX), Rituximab + HD- Methotrexate (MTX), procarbazine
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Chronic Hepatitis C
- Interventions
- Debio 025, Peg-IFNα2a, Ribavirin
- Drug
- Lead sponsor
- Debiopharm International SA
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 7
- States / cities
- La Jolla, California • Gainesville, Florida • Miami, Florida + 4 more
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- Acthar, Placebo
- Drug
- Lead sponsor
- Mallinckrodt
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 143 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 39
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 33 more
- Conditions
- Human Papilloma Virus Infection, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Oropharynx
- Interventions
- Transoral surgery, intensity-modulated radiation therapy, cisplatin, carboplatin
- Procedure · Radiation · Drug
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 519 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 58
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 44 more
- Conditions
- Pregnancy Prevention, Life Skill Development
- Interventions
- Healthy Adolescent Transitions (HAT) program
- Behavioral
- Lead sponsor
- Jack Stevens
- Other
- Eligibility
- 14 Years to 19 Years · Female only
- Enrollment
- 331 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2024
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal, Cancer of Lung, Cancer of the Lung, Lung Cancer, Neoplasms, Lung, Neoplasms, Pulmonary, Pulmonary Cancer, Pulmonary Neoplasms
- Interventions
- JDQ443, TNO155, tislelizumab
- Drug · Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 344 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • Boston, Massachusetts • Pittsburgh, Pennsylvania + 1 more
- Conditions
- Herpes Zoster, Shingles
- Interventions
- Amezosvatein Antigen High Dose Arm A, Amezosvatein Antigen Low Dose Arm B, Shingrix, Amezosvatein Adjuvant Dose Arm D, Amezosvatein Adjuvant Dose Arm F, Amezosvatein Adjuvant Dose Arm H, Amezosvatein Adjuvant Dose Arm J, Amezosvatein Adjuvant Dose Arm L
- Biological
- Lead sponsor
- Curevo Inc
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 1,516 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2032
- U.S. locations
- 14
- States / cities
- Tempe, Arizona • Coral Gables, Florida • Tampa, Florida + 11 more
- Conditions
- Heart Failure
- Interventions
- AZD3427, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 105 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 10
- States / cities
- Little Rock, Arkansas • Glendale, California • Daytona Beach, Florida + 7 more
- Conditions
- Covid19
- Interventions
- Ivermectin, Fluvoxamine, Fluticasone, Placebo, Montelukast, Metformin
- Drug · Other
- Lead sponsor
- Susanna Naggie, MD
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 10,956 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 110
- States / cities
- Chandler, Arizona • Gilbert, Arizona • Mesa, Arizona + 96 more
- Conditions
- Overweight, Obesity
- Interventions
- UBT251, Placebo
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 333 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 2
- States / cities
- Cypress, California • Overland Park, Kansas